Inhaled Drug Therapy Development for the Treatment of Migraine.

Inhaled Drug Therapy Development for the Treatment of Migraine. Expert Opin Pharmacother. 2016 Jul 14; Authors: Chua AL, Silberstein S Abstract INTRODUCTION: Currently, migraine abortive therapies are available in oral, intranasal, injectable, transdermal, suppository and intravenous routes. These formulations each come with their own set of challenges, such as poor bioavailability, intolerable side effects or inconvenient administration. The inhalation of substances, both medicinally and recreationally, is a commonly used method of drug administration but has been underutilized in the treatment of neurologic disorders such as migraine. Three drugs have been studied as potential inhalable treatments for acute migraine: dihydroergotamine (MAP0004), prochlorperazine (Staccato prochlorperazine), and loxapine (Staccato loxapine). AREAS COVERED: This review discusses the available literature describing the pharmacokinetics, tolerability and efficacy of MAP0004, Staccato prochlorperazine and Staccato loxapine, including data from Phase II and Phase III clinical trials. EXPERT OPINION: Inhaled DHE offers rapid absorption with a pharmacokinetic profile similar to IV administration. Improved side effect profile results from more selective binding at anti-migraine serotonergic receptors 5-HT1B and 5-HT1D. Inhaled prochlorperazine is rapidly absorbed and resulted in statistically significant migraine pain relief at 2 hours compa...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research